Up‐regulated NDUFA4L2 plays a critical role in the development of HPH, which mediates ROS production and proliferation of PASMCs, suggesting NDUFA4L2 as a potential new therapeutic target for PAH. This evidence concerns the gene COXFA4L2 and pulmonary arterial hypertension.